Inking Ono deal, Cyclenium searches space between small and large molecules for new candidates

14 December 2017
2019_biotech_test_vial_discovery_big

Privately-held Canadian firm Cyclenium Pharma has signed a drug discovery agreement with Ono Pharmaceutical (TYO: 4528), the Japanese firm whose fortune was made by the discovery of the groundbreaking I-O therapy Opdivo (nivolumab).

Cyclenium brings to the table its proprietary CMRT ‘macrocyclic’ technology, which targets the molecular space between traditional small molecules and large biologics.

The company was spun out from Tranzyme Pharma in 2013, one of the pioneers of the particular macrocycle technology the company is exploiting.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology